Market Place
Sourcing Support
Biogen Completes Acquisition of HI-Bio
03 Jul 2024 //
CONTRACT PHARMA
Hi-Bio Felzartamab Kidney Rejection: Positive Phase 2 Results In Recipients
25 May 2024 //
PR NEWSWIRE
Hi-Bio Felzartamab Igan Positive: Phase 2 Ignaz Interim Results At Era
24 May 2024 //
PR NEWSWIRE
Biogen in up to $1.8 bln deal as rare diseases take center stage
23 May 2024 //
REUTERS
HI-Bio to Present at the 61st European Renal Association (ERA) Congress
29 Mar 2024 //
PR NEWSWIRE
HI-Bio Receives FDA Orphan Designation for Felzartamab for in Kidney Transplant
21 Mar 2024 //
PR NEWSWIRE
HI-Bio Announces $95 Million Series B Financing
04 Jan 2024 //
PR NEWSWIRE
HI-Bio raises $95M as it pushes toward late-stage studies
04 Jan 2024 //
ENDPTS
HI-Bio Announces Felzartamab Granted Breakthrough Therapy Designation
31 Oct 2023 //
PR NEWSWIRE
HI-Bio Initiates Healthy Volunteer Study of HIB210 for Immune-Mediated Diseases
11 Jul 2023 //
PR NEWSWIRE
HI-Bio Receives FDA Orphan Drug Designation for Felzartamab
25 May 2023 //
PR NEWSWIRE
HI-Bio Announces Positive Phase 2 Data on Felzartamab for Membranous Nephropathy
11 Apr 2023 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.